TNXPTonix Pharmaceuticals Holdi...

Nasdaq tonixpharma.com


$ 1.32 $ -0.05 (-3.7 %)    

Friday, 21-Jun-2024 15:58:36 EDT
QQQ $ 479.17 $ 0.00 (0 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.75 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 1.3
$ 1.33
$ 0.00 x 0
$ 0.00 x 0
$ 1.29 - $ 1.35
$ 1.08 - $ 60.16
873,278
na
3.29M
$ -0.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 04-13-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 03-03-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-08-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tonix-pharmaceuticals-receives-formal-minutes-from-fda-pre-nda-meeting-for-tonmya-for-fibromyalgia-management-achieves-alignment-on-key-cmc-topics-including-drug-specifications-shelf-life-manufacturing-and-packaging

Company aligned with FDA on key CMC topicsTonix also has completed the second and final pre-New Drug Application (NDA) meeting ...

 tonix-pharmaceuticals-presented-poster-of-tonmya-for-the-management-of-fibromyalgia-at-the-annual-eular-2024

Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain...

 this-biopharma-stock-is-trading-23-higher-in-pre-market-after-wrapping-up-4m-public-offering

The public offering included 1,199,448 shares of common stock and pre-funded warrants to purchase up to 2,568,110 shares of com...

 tonix-pharmaceuticals-intends-to-offer-and-sell-shares-of-its-common-stock-or-pre-funded-warrants-in-lieu-thereof-no-terms-disclosed

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the...

 whats-going-on-with-tonix-pharmaceuticals-tnxp-stock

Tonix Pharmaceuticals shares are trading lower by 29% during Monday's session. The company effected a 1-for-32 reverse stoc...

 tonix-pharmaceuticals-presents-two-oral-presentations-and-one-poster-presentation-involving-tnx-1500-at-the-american-transplant-congress-2024

TNX-1500 displays potential as a monotherapy or combination therapy to prevent rejection in organ transplantation in allograft ...

 tonix-pharmaceuticals-to-present-new-data-on-tonmya-suggesting-activity-for-improvement-in-fibromyalgia-associated-depression-severity-in-an-oral-presentation-at-ascp-annual-meeting

Tonmya treatment was associated with improvement in depressive symptoms as measured by the Beck Depression Inventory-II In addi...

 tonix-pharmaceuticals-to-present-study-involving-tnx-1500-at-the-american-transplant-congress-2024

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with mar...